FirstString is a clinical stage biotech company leading the translation of cell-cell communication and cell-cell contact/adhesion science into a pipeline of drugs and medical applications for scar prevention, inflammation reduction, wound healing, and complex tissue regeneration. The company is currently advancing GranexinTM Gel, the topical formulation of a lead peptide, through three Phase II human clinical trials for scar reduction and treatment of chronic wounds. Preclinical studies are also being conducted with connexin-based peptides for indications having high unmet therapeutic needs in segments that include ophthalmology, central nervous system injuries, cardiac injuries, organ transplants, pulmonary, and oncology.
